低分子肝素治疗急性脑梗死的安全性及效果探讨

Discuss on safety and effect of low molecular weight heparin in the treatment of acute cerebral infarction

目的探讨低分子肝素治疗急性脑梗死的安全性及效果。方法 93例急性脑梗死患者,随机分为观察组(47例)和对照组(46例)。对照组给予常规治疗,观察组在常规治疗的基础上给予低分子肝素治疗。比较两组患者的治疗效果、不良反应发生情况及治疗前后血液学指标水平、美国国立卫生研究院卒中量表(NIHSS)评分、Barthel评分。结果观察组总有效率为93.62%,明显高于对照组的78.26%,差异具有统计学意义(P<0.05)。治疗后,观察组全血粘度、血浆粘度、纤维蛋白原水平、NIHSS评分均低于对照组,Barthel评分高于对照组,差异均具有统计学意义(P<0.05)。两组不良反应发生情况比较差异无统计学意义(P>0.05)。结论低分子肝素可提高急性脑梗死患者的治疗效果,促进神经功能恢复,且不良反应少。

Objective To discuss the safety and effect of low molecular weight heparin in the treatment of acute cerebral infarction. Methods A total of 93 patients with acute cerebral infarction were randomly divided into observation group（47 cases） and control group（46 cases）. The control group received conventional therapy, and the observation group received low molecular weight heparin on the basis of conventional therapy. Comparison were mad on treatment effects, incidence of adverse reactions, and hematological parameters, National Institute of Health Stroke scale（NIHSS） score, Barthel score before and after treatment between the two groups. Results The observation group had obviously higher total effective rate as 93.62% than 78.26% in the control group, and the difference was statistically significant（P〈0.05）. After treatment, the observation group had lower whole blood viscosity, plasma viscosity, fibrinogen level, NIHSS score than the control group, and higher Barthel score than the control group. Their difference was statistically significant（P〈0.05）. Both groups had no statistically significant difference in incidence of adverse reactions（P〉0.05）. Conclusion Low molecular weight heparin can improve the treatment effect of patients with acute cerebral infarction and promote nerve function recovery with fewer adverse reactions.